Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

octapharma ag - fibrinÓgeno humano - fibrinÓgeno humano....1 g

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

baxter healthcare corporation - fibrinÓgeno humano - fibrinÓgeno humano....91 mg / trombina humana....500 ui / aprotinina sintetica....3000 kiu / cloruro de calcio dihidratado....40 umol

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tranexamic acid 100 mg/ml - solution for injection - 100 mg/ml - active: tranexamic acid 100 mg/ml excipient: water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: · prostatectomy and bladder surgery · menorrhagia · epistaxis · conisation of the cervix · management of dental extraction in patients with coagulopathies · ulcerative colitis · haematuria · gastrointestinal haemorrhage. general fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery: · in obstetrical complications such as abruptio placentae and post-partum haemorrhage · in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tranexamic acid 500mg - tablet - 500 mg - active: tranexamic acid 500mg excipient: colloidal silicon dioxide hyprolose macrogol 8000 magnesium stearate   methacrylic acid copolymer microcrystalline cellulose povidone purified talc   titanium dioxide vanillin - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: · prostatectomy and bladder surgery · menorrhagia · epistaxis · conisation of the cervix · management of dental extraction in patients with coagulopathies · ulcerative colitis · haematuria · gastrointestinal haemorrhage. general fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery: · in obstetrical complications such as abruptio placentae and post-partum haemorrhage · in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranexamic acid 500mg - film coated tablet - 500 mg - active: tranexamic acid 500mg excipient: basic butylated methacrylate copolymer colloidal silicon dioxide croscarmellose sodium isopropyl alcohol macrogol 8000 magnesium stearate   microcrystalline cellulose povidone purified talc   purified water titanium dioxide vanillin - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: -prostatectomy and bladder surgery -menorrhagia -epistaxis -conisation of the cervix - management of dental extraction in patients with coagulopathies - ulcerative colitis - haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma) -gastrointestinal haemorrhage general fibrinolysis as in prostatic and pancreatic cancer; after thoracic and other major surgery: - in obstetrical complications such as abruptio placentae and post-partum haemorrhage - in leukaemia and liver diseases and in connection with thrombolytic therapy with streptokinase hereditary angioneurotic oedema. for the reduction of peri– and post-operative blood loss and the need for blood transfusion in adult patients undergoing cardiac surgery or total knee arthroplasty or total hip arthroplasty. for the reduction of peri- and post-operative blood loss and the need for blood transfusion in paediatric patients undergoing cardiac surgery.

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - tranexamic acid - injection - 100 mg/ml - tranexamic acid 100 mg/ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - tranexamic acid - tablet, film coated - 500 mg - tranexamic acid 500 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tranexamic acid 100 mg/ml - solution for injection - 100 mg/ml - active: tranexamic acid 100 mg/ml excipient: nitrogen water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. localfibrinolysis may occur in the following conditions: · prostatectomy and bladder surgery · menorrhagia · epistaxis · conisation of the cervix · management of dental extraction in patients with coagulopathies · ulcerative colitis · haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma (also see precautions). · gastrointestinal haemorrhage

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tranexamic acid 100 mg/ml - solution for injection - 100 mg/ml - active: tranexamic acid 100 mg/ml excipient: nitrogen water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. localfibrinolysis may occur in the following conditions: · prostatectomy and bladder surgery · menorrhagia · epistaxis · conisation of the cervix · management of dental extraction in patients with coagulopathies · ulcerative colitis · haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma (also see precautions). · gastrointestinal haemorrhage

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - tranexamic acid 100 mg/ml;   - solution for injection - 500 mg/5ml - active: tranexamic acid 100 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. local fibrinolysis may occur in the following conditions: - prostatectomy and bladder surgery - menorrhagia - epistaxis - conisation of the cervix - management of dental extraction in patients with coagulopathies - ulcerative colitis - haematuria (tranexamic acid therapy is not indicated in haematuria caused by diseases of the renal parenchyma (also see precautions). - gastrointestinal haemorrhage.